Prevalence and risk factors of sexual dysfunction in female participants with rheumatoid arthritis: a systematic review and meta-analysis.

Autor:	Huang J; Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311200, China., Guo C; Department of Urology, Chengfei Hospital, Chengdu, 610000, China., Sun J; Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311200, China., Hua R; Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311200, China., Fan Y; Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311200, China.
Jazyk:	angličtina
Zdroj:	The journal of sexual medicine [J Sex Med] 2024 Oct 31; Vol. 21 (11), pp. 1037-1046.
DOI:	10.1093/jsxmed/qdae114
Abstrakt:	Background: The prevalence and risk factors of female sexual dysfunction (FSD) in female participants with rheumatoid arthritis (RA) were reported with inconsistent results. However, no systematic review and meta-analysis of pooled data provide reliable estimates of FSD prevalence in female participants with RA. Aim: To investigate the global prevalence and risk factors of FSD in female participants with RA and to analyze the association between FSD risk and RA. Methods: The study search of this systematic review and meta-analysis was conducted through PubMed, Cochrane Library, Web of Science, and Embase from the inception date to December 10, 2023. Random effects meta-analysis was performed to derive the pooled prevalence. Q and I2 tests were used to analyze heterogeneity among the studies. Subgroup analyses and meta-regression were used to detect the sources of heterogeneity. Outcomes: The pooled prevalence of FSD in female participants with RA was calculated, and odds ratios (ORs) and 95% CIs were used to assess the strength of the association between FSD-related risk factors and RA. Results: A total of 13 studies were included in our analysis, involving 2327 participants. The pooled prevalence of FSD in female participants with RA was 49.1% (95% CI, 38.2%-60%). The participants with RA had a higher risk of FSD than healthy controls (OR, 3.10; 95% CI, 1.74-5.53). The significant risk factors of FSD in female participants with RA were depression status (OR, 1.42; 95% CI, 0.88-2.29) and menopause (OR, 5.46; 95% CI, 2.04-14.63). Clinical Implications: Female participants with RA had a significantly increased prevalence of FSD, indicating that sexual function in female participants with RA should be concerned by clinicians. Strengths and Limitations: The strength of this study is that it is the first meta-analysis to assess the global prevalence and risk factors of FSD in female participants with RA. A limitation is that the results, after the articles were pooled, showed significant heterogeneity and publication bias. Conclusions: The present systematic review and meta-analysis revealed that the overall prevalence of FSD in female participants with RA was 49.1%, indicating a significant association between FSD risk and RA among females. Moreover, menopause and depression status were significantly associated with FSD in female participants with RA. (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Sexual Medicine. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu